Skip to main
PACB
PACB logo

PACB Stock Forecast & Price Target

PACB Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Pacific Biosciences of California Inc. has shown promising trends in the placement and utilization of its Revio sequencing platform, contributing positively to its near-term guidance and long-term targets. The company’s management expresses confidence in returning to growth this year, supported by a strong organic profile and recent strategic acquisitions. Additionally, the potential for future mergers and acquisitions may enhance its market position, despite a cautious outlook in light of the uncertain macroeconomic environment.

Bears say

Pacific Biosciences of California Inc faces a challenging financial outlook due to stagnant utilization rates and weaker-than-expected demand for its new instruments, which jeopardizes its 2026 financial targets. Furthermore, persistent demand weakness in key markets like China, coupled with tightening research budgets and diminished funding for the life sciences sector, threatens the company's growth potential. Additionally, increased competitive pressures could result in a loss of market share, further adversely affecting the company's financial results.

PACB has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacific Biosciences of California (PACB) Forecast

Analysts have given PACB a Buy based on their latest research and market trends.

According to 15 analysts, PACB has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacific Biosciences of California (PACB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.